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Elevated levels of epidermal growth factor receptor in head and neck cancer have been extensively reported, and are
correlated with poor prognosis. The combination of cisplatin and 5-ﬂuorouracil is a standard treatment regimen for head and
neck cancer, with radiation representing another therapeutic option. Six head and neck cancer cell lines were used to study
the cytotoxic effects of combining ZD1839 (‘Iressa’), a new selective epidermal growth factor receptor tyrosine kinase
inhibitor, and radiation. Two of the cell lines were also used to study the combination of ZD1839 and cisplatin/5-ﬂuorouracil.
Cytotoxic effects were assessed by the MTT test. The results indicated that ZD1839 applied before radiation gave the best
effects (P=0.002); an effect that was strongest in those p53-mutated cell lines that express the highest epidermal growth
factor receptor levels. The effects of ZD1839 with cisplatin and/or 5-ﬂuorouracil were sequence dependent (P50.003), with
the best results achieved when ZD1839 was applied ﬁrst. For the triple combinations, ZD1839 applied before cisplatin and 5-
ﬂuorouracil resulted in a slight synergistic effect (P=0.03), although the effect was greater when ZD1839 was applied both
before and during cytotoxic drug exposure. In conclusion, ZD1839 applied before radiation and before and/or during cisplatin/
5-ﬂuorouracil may improve the efﬁcacy of treatment for head and neck cancer.
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Epidermal growth factor receptor (EGFR) has been particularly
well studied in head and neck cancer (HNC) because of its associa-
tion with the cellular mechanisms involved in tumour progression.
High levels of EGFR expression have been correlated with poor
prognosis (Santini et al, 1991; Dassonville et al, 1993). EGFR
signalling has been found to control not only cell growth, but also
angiogenesis and DNA repair (Wheeler et al, 1999; Schlessinger,
2000), and has recently been assessed as an innovative target in
cancer therapy and particularly in HNC. To date, clinical studies
in this area have involved the administration of cetuximab
(C225, a chimeric monoclonal antibody), either alone or in combi-
nation with chemotherapy or radiotherapy, to patients with
advanced head and neck squamous cell carcinoma (Ezekiel et al,
1999; Huang et al, 1999; Mendelsohn et al, 1999; Baselga et al,
2000; Huang and Harari, 2000; Milas et al, 2000). More recently,
a wide range of small-molecule tyrosine kinase inhibitors have been
developed, and one of the most advanced in this class of
compounds is ZD1839 (‘Iressa’), which is a quinazoline derivative.
This agent interacts speciﬁcally with the highly conserved ATP
binding site of the tyrosine kinase domain of EGFR, resulting in
inhibition of ligand-induced EGFR activation, and blockade of
signal transduction pathways (Ciardiello et al, 2000; Sirotnak et
al, 2000).
The cisplatin/5-ﬂuorouracil (5-FU) regimen is considered to be
a standard chemotherapy regimen in the treatment of advanced
HNC as part of an organ-conserving strategy (Taylor et al, 1997;
Brizel et al, 1998; Calais et al, 1999). Another standard treatment
is the combination of external beam radiation therapy with surgical
extirpation (Bensadoun et al, 1998; Fu et al, 2000; Vokes et al,
2000). Despite the effectiveness of these treatments, the survival
rates vary according to the tumour site and stage, and globally,
prognosis remains poor (Vokes et al, 1993). Thus, one interesting
and promising research direction for altering the natural history of
HNC could be a molecular-targeted therapy against EGFR in asso-
ciation with one of the standard therapeutic strategies.
Experimental data have indicated that application of EGFR-target-
ing agents can not only slow down cell proliferation, but also
improve apoptotic capacities and decrease DNA repair. These
observations suggest that EGFR targeting can lead to chemo- and
radiosensitisation and recent experimental results tend to conﬁrm
this view (Huang et al, 1999).
The aim of this study was two-fold: ﬁrstly, to explore the
sequence-dependent cytotoxic effects of combining ZD1839 with
radiation using a panel of six human head and neck squamous cell
carcinoma cell lines; and secondly, to investigate the sequence-
dependent cytotoxic effects of combining ZD1839 with cisplatin
and/or 5-FU on two of the cell lines from the panel. This preclini-
cal work was undertaken to serve as a rationale to support ongoing
clinical investigations of ZD1839 in HNC patients.
MATERIALS AND METHODS
Chemicals
ZD1839 was kindly provided by AstraZeneca. A 50 mM working
solution in dimethysulphoxide (DMSO) was prepared before use.
Human recombinant
125I-EGF (ref IM 196, speciﬁc activity
4514610
10 Bq mmol
71, 92.5610
4 Bq per 250 ml) and unlabelled
human recombinant EGF (ref ARN 5100) were obtained from
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RPMI 1640 and glutamine were purchased from Whittaker
(Verviers, Belgium). Foetal bovine serum (FBS) was obtained
from Dutscher (Brumath, France). Penicillin and streptomycin
were from Meyrieux (Lyons, France). Transferrin and insulin
were purchased from Flow (Irvine, Scotland). Bovine serum
albumin (BSA), 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide (MTT) and DMSO were purchased from Sigma
(St Quentin Fallavier, France).
Cell lines
Six HNC cell lines of human origin were used (CAL27, CAL33,
CAL60, CAL166, Hep-2, Detroit562) (Table 1). Cells were routinely
cultured in DMEM supplemented with 10% FBS, 2 mM glutamine,
600 mgl
71 insulin, 500 mgl
71 transferrin, 50000 units l
71 penicil-
lin and 80 mM streptomycin in a fully humidiﬁed incubator (Sanyo,
Japan) at 378C in an atmosphere containing 8% CO2.
EGFR assay
EGFR expression was assayed by competitive analysis and Scatch-
ard plots as previously described in human cancer cell lines
(Olivier et al, 1990). Cells were grown in 24-well plates (10
5 cells
per well) in 10% FBS-DMEM at 378C. At 80–90% conﬂuence,
cells were rinsed three times with 500 ml RPMI 1640 containing
0.1% BSA at 2–48C (plates placed on a tray with ice). Plates were
then incubated for 30 min with the same medium (500 ml per well)
at 48C. Cells were ﬁrst screened for their capacity to bind EGF
speciﬁcally. Total binding was measured after incubation with
0.2 nM
125I-EGF (3 h, 48C, 0.1% BSA–RPMI); non-speciﬁc bind-
ing was measured in the presence of an excess of unlabelled EGF
(20 nM). With no exception, the six tested cell lines exhibited
EGF binding and their precise EGFR content was then measured.
Cells were incubated in the RPMI medium for 3 h, at 48C in the
presence of various concentrations of
125I-EGF (0.01, 0.02, 0.04,
0.08, 0.12, 0.18, 0.20 nM); for higher EGF concentrations, cells were
incubated with 0.2 nM
125I-EGF with increasing concentrations of
unlabelled EGF (0.05, 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 20, 200 nM).
Plates were placed on ice to stop the reaction, and the supernatant
was removed from each well. Cells were washed twice with phos-
phate-buffered saline (PBS) containing 0.1% BSA (48C, 500 ml
per well). After removal of the supernatant, cells were solubilised
in 1 M NaOH at 378C (500 ml per well for 30 min). The radio-
activity of each well was determined by gamma counting. Results
were expressed in fmol per mg cell protein. Scatchard analysis
was used to calculate the number of receptor sites per cell (N)
and the dissociation constant (Kd). Each point of every Scatchard
plot was performed in quadruplicate. Cells were counted in four
wells run in parallel, resuspended in 200 ml PBS at room tempera-
ture and counted with a haemocytometer. Experiments were
performed in duplicate only, because of the intrinsic reproduci-
bility of the assay (coefﬁcient of variance=7.3%, n=4).
Determination of p53 status
DNA was extracted from all head and neck cell lines of the panel.
Exons 4 to 8 were screened for mutations by use of denaturing
gradient gel electrophoresis in accordance with the method
described by Hamelin et al (1993) for exons 5, 7, and 8, and the
method of Gulberg et al (1997) for exons 4 and 6. Exon 9 was
screened for mutations by the method described by Cabelguenne
et al (2000). Polymerase chain reaction (PCR) ampliﬁcation
products were loaded onto a 6.5% polyacrylamide gel that
contained an appropriate gradient of urea and formamide. After
electrophoresis, gels were stained with ethidium bromide. Tumours
that showed an electrophoresis variant pattern were ampliﬁed and
sequenced for each variant exon. PCR products were puriﬁed with
QIAquick PCR Puriﬁcation Kit (QIAGEN SA, Courtabeuf, France)
and sequenced on both strands on an ABI 310 genetic analyser (PE
Applied Biosystems, Courtabeuf, France). A Big Dye Terminator
sequencing kit (PE Applied Biosystems) was used in accordance
to the manufacturer’s instructions; this step was followed by
ethanol precipitation to remove non-incorporated dyes. Sequences
were analysed by Sequence Analysis 3.0 (PE Applied Biosystems).
Evaluation of radiotoxicity
Cells were irradiated with gamma rays during exponential cell
growth as monolayers in 96-well microtitration plates using a
60Co unit at a dose rate of 1 Gy min
71. Dose-effect curves were
established for all six head and neck cell lines using a total of 10
doses (0.5, 1, 2, 3, 4, 6, 8, 10, 12, 15 Gy). Sequence-dependent
cytotoxic effects of binary combinations of ZD1839 (0.2–
200 mM) with ionising radiation were then evaluated using eight
doses of ionising radiation, ranging from 0.5 to 10 Gy for CAL27
and CAL33, and from 2 to 15 Gy for CAL60, CAL166, Hep-2
and Detroit562 (the radiation doses were selected from the above
experiments to encompass more precisely the zone of sensitivity).
Cells were maintained in DMEM supplemented with 10% FBS
during all radiation exposures, which were performed at room
temperature.
Determination of the cytotoxic effects of radiation alone
Cells were seeded in 96-well microtitration plates (100 ml per well)
to obtain exponential growth for the whole duration of the experi-
ment: initial cell densities were 2500 (CAL27 and Hep-2), 3000
(CAL33 and Detroit562), 4500 (CAL166) and 5000 (CAL60) cells
per well.
The cells were exposed to ionising radiation 48 h later (dose
previously described) and the MTT assay was performed 48 h after
that. Control cells received no radiation treatment.
Determination of cytotoxicity using ZD1839 in combination
with radiation Cells were seeded in 96-well microtitration plates
(100 ml per well) to obtain exponential growth for the whole dura-
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Table 1 Head and neck cancer cell line characteristics
a
EGFR levels Doubling IC50 IC50 IC50 IC50
Cell line Origin (fmol mg
71 protein) p53 status time (h) radiation (Gy) cisplatin (mM) 5-FU (mM) ZD1839 (mM)
CAL27 CAL 8258 (311) mutant (exon 6) 18.2 (1.5) 6.2 (1.1) 2.4 (0.1) 4.1 (0.8) 17.5 (2.4)
CAL33 CAL 33794 (624) mutant (exon 5) 17.5 (0.1) 2.6 (0.4) 5.7 (1.2) 2.7 (1.9) 6.07 (0.8)
CAL60 CAL 2703 (101) mutant (exon 7) 11.8 (0.2) 5.1 (0.1) 2.2 (0.1) 1.1 (0.2) 11.4 (0.9)
CAL166 CAL 3253 (126) wild type 13.1 (1.0) 6.2 (0.8) 9.7 (0.6) 5.4 (0.6) 22.8 (4.8)
Hep-2 ATCC 388 (27) wild type 10.9 (1.0) 9.8 (0.3) 7.1 (1.7) 5.6 (1.0) 31.1 (2.4)
Detroit562 ATCC 668 (45) mutant (exon 5) 14.8 (0.4) 7.7 (0.1) 12.6 (1.1) 31.7 (1.1) 20.6 (1.5)
aMean values (standard deviation), at least two separate experiments done at distance for EGFR content, and three different experiments for other deter-
minations; CAL, Center Antoine Lacassagne; ATCC, American Type Culture Collection, Rockville.
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plate, one ZD1839 concentration and one radiation dose were
tested. Only half of each plate was irradiated in order to measure
on the same plate the effects of ZD1839 alone (20 wells), radiation
alone (ﬁve wells), ZD1839 combined with radiation (20 wells) and
a control (no radiation, no ZD1839; ﬁve wells).
Forty-eight hours after seeding the cells, three different
sequences of radiation and 48-h incubations of ZD1839 were
compared: (a) ZD1839 (48 h) followed by radiation, then medium
for 48 h; (b) concomitant ZD1839 (48 h) and ionising radiation
(radiation delivered in the middle of ZD1839 exposure), followed
by medium for 48 h; (c) ionising radiation prior to ZD1839
(48 h), then medium for 48 h.
Growth inhibition was assessed 168 h after cell seeding by
using the MTT test as described below (Carmichael et al,
1987). Cells were washed with PBS and incubated with MTT;
after 2 h of exposure, MTT was released and ﬁxation was
revealed by the addition of DMSO (100 ml). Absorbance at
450 nm was measured using a microplate reader (Labsystems,
Helsinki, Finland). Results were expressed as the relative percen-
tage of absorbance compared with controls without drug. Cell
sensitivity to the tested drugs was expressed by IC50 (concentra-
tion leading to 50% cell survival). Triplicate determinations were
made in separate experiments.
Evaluation of cisplatin and/or 5-FU cytotoxicity
Cells were seeded in 96-well microtitration plates (100 ml per
well) to obtain exponential growth for the duration of the
experiments (initial cell density was 2500 and 3000 cells per well
for Hep-2 and CAL33, respectively). Forty-eight hours after seed-
ing, cells were exposed to ZD1839 and cisplatin and/or 5-FU in
a variety of sequences. In all cases, cells were exposed to ZD1839
for 48 h, and the cisplatin/5-FU sequence was constant (cisplatin
applied for 2 h prior to exposure to 5-FU for 48 h). The
sequence of ZD1839 varied: (a) ZD1839 (48 h) followed by
cisplatin and/or 5-FU; (b) concomitant ZD1839 and cisplatin
and/or 5-FU (the exposure to ZD1839 was 50 h); (c) ZD1839
prior to and during cisplatin/5-FU exposure (ZD1839 was given
for 48 h before cisplatin/5-FU and then for 50 h concomitant
with cisplatin/5-FU, making 98 h in total) followed by medium
for 48 h; (d) cisplatin/5-FU prior to ZD1839 followed by
medium for 48 h. Eleven concentrations were tested for each
drug: ZD1839 0.2–200 mM; cisplatin 0.1–200 mM; 5-FU 0.22–
220 mM. The cisplatin/5-FU combination was tested at a constant
concentration ratio of the drugs for a given cell line, the ratio
being dictated by the drug sensitivity and close to the ratio of
the IC50 for each drug.
Thereafter, growth inhibition was assessed 48 h after the end of
the experiment (in medium alone) by the MTT test described
above. Experimental conditions were tested in sextuplicate (six
wells of the 96-well plate per experimental condition) and separate
experiments were performed in triplicate. The dose-effect curves
were analysed using Prism software (GraphPad Software, San
Diego, CA, USA).
Combination index (CI) calculations and determination of
the potentiation factor
The cytotoxic effects obtained with the different ZD1839/cisplatin/
5-FU combinations were analysed according to the Chou and
Talalay (1984) method on Calcusyn software (Biosoft,
Cambridge, UK). Interaction between the double combinations
(ZD1839 plus either cisplatin or 5-FU), or the triple combina-
tions (ZD1839 plus cisplatin and 5-FU) was assessed by means
of an automatically computed combination index (CI). CI was
determined at 50 and 75% cell death, and was deﬁned as
follows:
CIAB   DA=AB=DA  DB=AB=DB aDA=AAB  DB=AB=DADB
where CIAB  CI for a fixed effect F for the combination of cytotoxic A
and cytotoxic B:
DA=AB  concentration of cytotoxic A in the combination A  B giving
an effect F:
DB=AB  concentration of cytotoxic B in the combination A  B giving
an effect F:
DA  concentration of cytotoxic A alone giving an effect F:
DB  concentration of cytotoxic B alone giving an effect F:
a  parameter with value 0 when A and B are mutually exclusive and
1 when A and B are mutually non-exclusive:
The combination index indicated: synergism 50.8; additivity 40.8
and 51.2; antagonism 41.2; slight synergistic and additive cyto-
toxic activity for values of 0.8 and 1.2, respectively.
The cytotoxic effects obtained with the different ionising radia-
tion/ZD1839 combinations were also analysed according to the
Chou and Talalay (1984) method as described above. CIs were
determined at 50 and 75% cell death. The application of the Chou
and Talalay model recommends the use of cytotoxic agents at a
ﬁxed dose ratio (for example, the ratio of their IC50s). However,
in the case of ZD1839 and radiation, this strategy would not have
been feasible because the dose-effect curves of each cytotoxic agent
acting alone are too different (e.g. IC90/IC10=50 for ZD1839 and
2.8 for radiation (CAL33 cell line)). Consequently, ZD1839 and
radiation were combined at equitoxic effects (i.e. doses were
applied in the combination that would have produced the same
cytotoxic effect if given alone); it follows that the ratio between
the concentration of ZD1839 and the radiation dose varied from
4610
77 up to 2610
75 when progressing from low to high cyto-
toxic effect. When using non-constant ratios between the doses, the
Chou and Talalay Calcusyn programme does not allow direct
calculation of the CIs at a ﬁxed ﬁnal cell death (50 and 75% in
the present case). Thus, in order to compare CI at ﬁxed values,
i.e. CI50 or CI75, we graphically interpolated between values
obtained from the experimental points (11 points generated by
the programme between 10 and 90% of ﬁnal death).
The potentiation factor of ionising radiation by ZD1839 was
deﬁned as the ratio of the IC50 of ionising radiation alone to the
IC50 of the combination (ZD1839 plus ionising radiation); higher
potentiation factors indicate greater cytotoxicity. Potentiation
factor I was obtained using sequence I (ZD1839 (48 h) followed
by radiation, then medium for 48 h). Potentiation factor II used
sequence II (concomitant ZD1839 (48 h) and ionising radiation,
radiation delivered in the middle of the ZD1839 exposure), and
potentiation factor III used sequence III (ionising radiation prior
to ZD1839 (48 h), then medium for 48 h).
Statistical analysis
For the panel of cell lines, the relationship between EGFR expres-
sion and response to ionizing radiation was analysed by plotting
IC50 values for radiation against the respective EGFR content.
The Friedman non-parametric rank test was used to analyse the
impact of the sequence ZD1839/cisplatin/5-FU (CI values) or
ZD1839/radiation and to compare the different sequences combin-
ing ZD1839 and radiation on the basis of the potentiation factors.
The correlation coefﬁcients (r) and the P-values were computed
using SPSS software (Chicago, IL, USA). A P-value of less than
0.05 was considered to be statistically signiﬁcant.
RESULTS
The study panel of human squamous cell carcinoma cells showed
substantial variability in EGFR expression, ranging from 388
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 819–827(Hep-2) to 33 794 (CAL33) fmol per mg cell protein. Four of the
six cell lines were found to be mutated for p53 gene; CAL166 and
Hep-2 were p53 wild type (Table 1).
Hep-2 cells were the most radioresistant (IC50 9.8+0.3 Gy), and
CAL33 cells the most radiosensitive (IC50 2.6+0.4 Gy). Figure 1
shows dose-survival curves following irradiation for Hep-2 and
CAL33 cells. Over the panel of cell lines, growth inhibition was
more pronounced in EGFR-overexpressing cell lines than it was
in cell lines expressing low levels of EGFR (Table 1). A statistically
signiﬁcant linear inverse correlation was found between EGFR
cellular content and IC50 for radiation (P=0.0091, r
2=0.848)
(Figure 2). No statistically signiﬁcant correlation was found
between EGFR levels and cell doubling time for the six head and
neck cell lines (P=0.093, r
2=0.548).
Typical dose-effect curves for the different ZD1839/radiation
exposure combinations are shown in Figure 3 for CAL33. In all cell
lines, pretreatment with ZD1839 followed by ionising radiation
(sequence I) produced a leftward shift of the concentration-
response curves, indicating a greater cytotoxic effect. The CI values
computed at 50 and 75% cell lethality are given in Table 2. It
appears that ZD1839 applied 48 h before radiation (sequence I)
led to lower CI values in all head and neck cell lines (P=0.002).
More precisely the best synergistic effects were observed in the
p53-mutant cell lines that express the highest EGFR levels
(CAL27, CAL33, CAL60). Typical examples of CI/fractional effect
curves are illustrated in Figure 4 for CAL33.
Table 3 gives the potentiation factors for ZD1839 and ionizing
radiation. Statistical analyses indicated that the relative contribu-
tions of the two treatments are signiﬁcantly different depending
upon the sequence (P=0.001). The greatest contribution to the
overall cytotoxicity of the combination came from ZD1839 applied
48 h before irradiation (sequence I; highest relative contribution)
and the smallest from ZD1839 following irradiation (sequence III).
The order of association between ZD1839 and combined cyto-
toxic drugs had a signiﬁcant impact on their interaction. For
both cell lines, application of the Wilcoxon test shows that the
association between ZD1839 and cisplatin alone gives supra-
additive effects more frequently when ZD1839 is applied ﬁrst; the
same conclusions are true for ZD1839 combined with 5-FU, with
mainly synergistic effects when ZD1839 is given before 5-FU (P
50.003) (Table 4). When ZD1839 was applied during or after each
of these drugs, effects were usually additive or antagonistic. With
the triple combination (ZD1839, cisplatin, 5-FU), the effects were
synergistic when ZD1839 was applied ﬁrst, in both Hep-2 and
CAL33 cells (P=0.003) (Table 4). In contrast, when ZD1839 was
applied during or after cisplatin/5-FU there were antagonistic or
additive effects. Interestingly, the optimal result (lowest CI value)
was obtained with sequence III, in which ZD1839 is applied before
and during cisplatin/5-FU (Table 4). Typical dose-effect curves
comparing sequences I and III are given in Figure 5 for Hep-2
and CAL33.
DISCUSSION
Squamous cell carcinomas in the aerodigestive tract remain a
signiﬁcant public health problem (Vokes et al, 1993). Even with
multimodal therapy, the long-term remission rate for these cancers
is only around 50–60%. External beam radiotherapy represents
one of the main therapeutic tools in HNC, producing major anti-
tumour responses when used in conjunction with both cisplatin
and 5-FU in either induction or adjuvant treatment settings (Vokes
et al, 2000). A recent meta-analysis has shown that a substantial
survival beneﬁt can be obtained by chemo-/radiotherapy combina-
tion in advanced HNC (Pignon et al, 2000). The challenge in this
pathology is to incorporate new agents into established regimens in
order to obtain a signiﬁcant impact on overall outcome. Over the
past decade, comprehensive data have been accumulated that
strongly support a role for EGFR and its ligands in tumour devel-
opment and growth. This is particularly true for squamous cell
carcinoma of the head and neck, where EGFR is considered to
be one of the major prognostic factors (Santini et al, 1991; Dasson-
ville et al, 1993; Salomon et al, 1995; Grandis et al, 1996, 1998;
Maurizi et al, 1996). As a result, EGFR has become an attractive
target for novel anticancer therapies, particularly in HNC.
Previous studies have shown that stimulation of the EGFR
signalling pathway leads to radioresistance both in vitro and in vivo
(Wollman et al, 1994; Miyaguchi et al, 1998; Akimoto et al, 1999;
Dent et al, 1999). Interestingly, in the present study, we observed a
strong positive association between EGFR level and radiosensitivity,
which is in agreement with previous results of Bonner et al (1994,
1998, 2000). Among a panel of human tumour cell lines, these
authors found that the cell line expressing the lowest EGFR levels
demonstrated the greatest radioresistance, and that the greatest
growth inhibition was observed for the cell line with the highest
EGFR content. In addition, there are some in vitro reports suggest-
ing an EGF-related radiosensitisation. For instance, Kwok and
Sutherland (1989, 1991) have shown that EGF-related radiosensiti-
zation may be EGFR-density dependent. A link between the
presence of transforming growth factor alpha (TGFa) and radio-
sensitivity was also suggested by the clinical data reported by
Sauter et al (1994) and Wen et al (1996). More precisely, Sauter
et al (1994) found that low plasma TGFa levels were associated
with radioresistance in patients with squamous carcinoma of the
tongue. Wen et al (1996) reported that the recurrence rates of early
laryngeal cancer treated with radiotherapy correlated with TGFa
but not with EGFR. Thus, it appears that not only EGFR but also
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Figure 1 Dose-survival curves following ionising radiation for Hep-2 and
CAL33 cells.
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British Journal of Cancer (2002) 86(5), 819–827 ã 2002 Cancer Research UKthe tumoural content of its speciﬁc ligands may play an important
role in radiosensitivity. Cell doubling time and EGFR content were
not found to be correlated in the present study. Thus the impact of
EGFR on radiosensitivity is not explicable by EGFR-dependent
modiﬁcations of cell kinetic characteristics, which could enhance
the action of irradiation. The classical view of the cellular effects
of ionising radiation consists of an initial event involving the
induction of DNA damage, in addition to the activation of several
intracellular signalling cascades that have commonly been regarded
as mitogenic, including the Raf-MEK-Erk kinase cascade (Todd et
al, 1999). DNA damage is modulated by metabolic DNA repair
processes. Interestingly, Bandyopadhyay et al (1998) have shown
that EGFR-mediated signalling may control the activity of DNA-
PK, an enzyme directly involved in DNA damage repair; more
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Figure 3 Dose-effect curves for the different ZD1839/radiation exposure combinations for CAL33 cells: (A) sequence I, (B) sequence II, (C) sequence
III. For each combination sequence of ZD1839 and radiation, the dose-effect curve of the combination was compared with the dose-effect curves of
ZD1839 alone and radiation alone. Radiation dose ranged from 0.5 to 10 Gy.
Table 2 CI values
a according to the different sequences of ZD1839/radiation
50% CI 75% CI
Cell line Sequence I Sequence II Sequence III Sequence I Sequence II Sequence III
CAL27 0.4 (0.1) 1.5 (0.1) 3.1 (0.1) 0.8 (0.4) 1.5 (0.1) 3.1 (1.0)
CAL33 0.5 (0.1) 1.1 (0.1) 1.9 (0.2) 0.8 (0.0) 1.6 (0.8) 2.8 (0.3)
CAL60 0.7 (0.0) 0.7 (0.1) 1.4 (0.1) 0.5 (0.1) 0.9 (0.2) 1.7 (0.2)
CAL166 0.9 (0.1) 2.1 (0.3) 1.8 (0.1) 2.2 (0.4) 1.5 (0.1) 1.8 (0.3)
Hep-2 0.9 (0.7) 2.5 (0.0) 2.9 (1.2) 1.3 (0.3) 2.2 (1.0) 1.1 (0.2)
Detroit562 1.2 (0.1) 16.2 (3.2) 2.2 (0.4) 1.1 (0.2) 15.2 (0.2) 2.0 (0.3)
a50 and 75% mean (standard deviation) CI values (at least three separate experiments) computed at 50 and 75% of growth inhibitory
effects; sequence I, ZD1839 applied before radiation; sequence II ZD1839 applied during radiation; sequence III, ZD1839 applied after
radiation. The Friedman non-parametric rank test was used to analyse the impact of the sequence of treatment on the whole cell line
panel, P=0.002.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 819–827precisely, from their work, high EGFR expression could maintain a
high level of signalling, which would be associated with high basal
levels of DNA repair capacity. However, this does not appear to
explain the observations reported here. An approach used by Lewis
et al (2000), examining the whole pattern of MAP kinase pathway
signalling targets, could help to elucidate the molecular origins of
the present observation of a radiosensitivity linked to high tumour-
al EGFR levels.
A strong positive interaction between irradiation and ZD1839,
when the ZD1839 was applied before the radiation, was demon-
strated in the present study (Tables 2 and 3). This could be
explained by an intrinsic activity of ZD1839 as radiosensitiser, as
has previously been shown for cetuximab, another EGFR-targeting
drug (Ezekiel et al, 1999; Huang et al, 1999; Mendelsohn et al,
1999; Baselga et al, 2000; Huang and Harari, 2000; Milas et al,
2000), and also for trastuzumab (Herceptin
TM), a HER-2-targeting
drug (Pegram et al, 1998; Pietras et al, 1999; Pegram and Slamon,
2000). Trastuzumab increased the radiosensitivity of HER-2-over-
expressing MCF7 breast cancer cells as measured by in vitro
colony-forming assays, and the combination of trastuzumab and
radiation showed synergistic tumour reduction in nude mice
(Pietras et al, 1999). According to Pietras et al (1999) the mechan-
ism of radiosensitization appears to involve both cell cycle
regulation and DNA repair. Interestingly, the application of
ZD1839 in our study was found to increase the percentage of cells
in the G1 phase (results not shown), which are particularly sensi-
tive to radiation (Teyssier et al, 1999). Thus, there are several
potential mechanisms of radiosensitisation by inhibitors of the
EGFR family; they may include favourable cell cycle reorganisation
and/or abrogation or attenuation of signals required for survival
during cell cycle arrest. Marked antagonistic effects were observed
when exposing cells to ZD1839 after irradiation (sequence III).
This observation may be related to the fact that irradiation is able
to upregulate EGFR phosphorylation in a similar manner to EGF
(Wan et al, 2001) and thus create the circonstances of opposite
effects to ZD1839.
Two cell lines of the initial panel of six were considered for
analysis of the association between ZD1839 and cytotoxic drugs.
We have recently demonstrated an inverse correlation between
p53 content (representative of p53 mutations) and EGFR levels
in a group of HNC patients (Etienne et al, 1999). Thus, the two
cell lines were selected because they are representative of human
HNC characteristics on the basis of their p53 status and EGFR
status: CAL33 is p53 mutant and has high EGFR expression, and
Hep-2 is p53 wild type and has low EGFR expression. We observed
synergistic effects when ZD1839 was applied before cisplatin and/or
5-FU in both cell lines (Table 4). The impact of ZD1839 on the
effects of the combined drugs was sequence dependent. The highest
synergistic effects were obtained when ZD1839 was applied before
and during exposure to cytotoxic drugs (Table 4). Previous in vivo
and in vitro studies have shown that the anti-EGFR receptor mono-
clonal antibody C225 can potentiate the effects of a number of
chemotherapeutic agents, including doxorubicin, paclitaxel and
cisplatin (Ezekiel et al, 1999; Mendelsohn et al, 1999; Huang et
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Figure 4 Typical examples of CI/fractional effects curves for CAL33 cells: (a) sequence I, (b) sequence II, (c) sequence III.
Table 3 Values of potentiation factors
a of ionising radiation by ZD1839
Potentiation Potentiation Potentiation
Cell line factor I factor II factor III
CAL27 2.7 (0.2) 2.2 (2.0) 0.5 (0.1)
CAL33 2.3 (1.5) 1.5 (1.4) 0.1 (0.1)
CAL60 3.7 (0.1) 0.5 (0.1) 0.6 (0.1)
CAL166 3.2 (0.4) 0.5 (0.2) 0.8 (0.1)
Hep-2 7.5 (2.1) 2.0 (0.8) 1.0 (0.2)
Detroit562 3.1 (0.0) 2.5 (0.0) 0.8 (0.1)
aMean (standard deviation) potentiation factor values (at least three separate experi-
ments); statistical analysis (Friedman non-parametric rank test) was used to compare
the different sequences combining ZD1839 and radiation on the basis of the poten-
tiation factors on the whole cell line panel, P=0.03.
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2000). The mechanisms by which receptor blockade by C225
augments the cytotoxic effect of anti-neoplastic agents was attri-
buted by these authors to cell cycle effects and an enhanced capa-
city for apoptosis by C225. The antiproliferative activity of ZD1839
combined with a number of cytotoxic drugs (cisplatin, carboplatin,
oxaliplatin, paclitaxel, docetaxel, doxorubibin, etoposide, topotecan
and raltitrexed) has been recently assessed in a variety of human
cancer cell lines (Ciardiello et al, 2000; Sirotnak et al, 2000). The
co-administration of ZD1839 was found to enhance the growth-
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Table 4 CI results in Hep-2 and CAL33 cell lines corresponding to concentration of drugs leading to 50% cell survival
Hep-2 CAL33
Treatment 50% CI, mean (s.d.) Combination effect 50% CI, mean (s.d.) Combination effect
Prior exposure to ZD1839
ZD1839+cisplatin 0.9 (0.2) Additive 0.8 (0.1) Synergistic
ZD1839+5-FU 0.6 (0.1) Synergistic 0.7 (0.3) Synergistic
ZD1839+cisplatin+5-FU 0.8 (0.1) Synergistic 0.7 (0.1) Synergistic
Concomitant exposure to ZD1839
ZD1839+cisplatin 1.1 (0.5) Additive 1.2 (0.6) Additive
ZD1839+5-FU 0.8 (0.3) Synergistic 1.5 (0.3) Antagonistic
ZD1839+cisplatin+5-FU 1.3 (0.4) Antagonistic 1.1 (0.5) Additive
Prior and concomitant exposure to ZD1839
ZD1839+cisplatin+5-FU 0.6 (0.2) Synergistic 0.4 (0.2) Synergistic
Exposure to ZD1839 after cisplatin and/or 5-FU
ZD1839+cisplatin 1.4 (0.3) Antagonistic 1.1 (0.2) Additive
ZD1839+5-FU 1.0 (0.2) Additive 1.3 (0.8) Antagonistic
ZD1839+cisplatin+5-FU 1.5 (0.4) Antagonistic 1.4 (0.8) Antagonistic
At least three separate experiments; ZD1839 applied for 48 h; cisplatin for 2 h; 5-FU for 48 h.
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Figure 5 Typical dose-effect curves comparing sequences I and III for (A, B) Hep-2 and (C, D) CAL33. Sequence I consisted of ZD1839, followed by
cisplatin/5-FU for 48 h; sequence III was ZD1839 applied ﬁrst and also during the cisplatin/5-FU exposure, followed by medium for 48 h.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 819–827inhibitory effects of all cytotoxic drugs tested. The present data
conﬁrm this interesting property of ZD1839 as a strong radio-
and chemosensitizer. In addition, the present study brings particu-
lar focus to the importance of the combination sequence: it is
shown that synergy is not a rule and that some antagonistic effects
may result from inappropriate sequences, e.g. where ZD1839 is
applied after the cytotoxic drugs (Table 4). In conclusion, the
present investigations into the combinations of ZD1839 and radia-
tion, and ZD1839 and cisplatin/5-FU, led to similar ﬁndings of
sequence-dependent synergy. Although an unavoidable gap does
exist between the bench and the bed side, these data may be useful
for the design of future clinical trials combining ZD1839 and cyto-
toxic agents.
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